Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antimony is a chemical element (symbol Sb, atomic number 51) and a metalloid that has been used medicinally for centuries, primarily as a treatment for leishmaniasis [8, 13]. In modern pharmacology, it is administered as pentavalent antimonial prodrugs, such as sodium stibogluconate and meglumine antimoniate, which are reduced to the active trivalent form (SbIII) within the target parasite [2, 10]. The primary mechanism of action involves the inhibition of trypanothione reductase, an essential enzyme for the parasite's redox balance, leading to oxidative stress and cell death [1, 8]. Additionally, antimony interferes with energy metabolism by inhibiting phosphofructokinase and may impair DNA replication through the inhibition of topoisomerase I [2, 5]. Beyond its antiparasitic role, antimony compounds are being investigated for their ability to inhibit human protein tyrosine phosphatases like SHP-1, which could have applications in cancer immunotherapy [9, 14]. Despite its efficacy, the therapeutic use of antimony is constrained by significant systemic toxicities, including cardiotoxicity and pancreatitis, and the emergence of widespread drug resistance in endemic regions [8, 16].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antimony (Sb) (Sb).